National Institute for Health and Care Excellence

Breast cancer

We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.
The National Institute for Health and Care Excellence

500,000 eligible to benefit from new non-hormonal treatment for hot flushes caused by menopause

A new treatment option for menopausal hot flushes and night sweats can be used in the NHS when hormone replacement therapy ...
National Institute for Health and Care Excellence

Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over

This guidance updates and replaces NICE technology appraisal guidance on ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over (TA1088). Next review: This guidance will be ...
National Institute for Health and Care Excellence

Published guidance, NICE advice and quality standards

Durvalumab with gemcitabine and cisplatin for neoadjuvant treatment then alone for adjuvant treatment of muscle-invasive bladder cancer TA1138 2 March 2026 2 March 2026 ...
National Institute for Health and Care Excellence

In consultation: Guidance and quality standards

Lutetium-177 vipivotide tetraxetan in combination for treating PSMA-positive hormone-sensitive metastatic prostate cancer ID6589 Consultation on suggested remit, draft scope and provisional ...
National Institute for Health and Care Excellence

Suspected sepsis: recognition, diagnosis and early management

This guideline has been updated and replaced by NICE's guidelines on suspected sepsis in people aged 16 or over (NG253), suspected sepsis in under 16s (NG254) and suspected sepsis in pregnant or ...
National Institute for Health and Care Excellence

Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy

Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy Technology appraisal guidance TA673 Published: 17 ...
National Institute for Health and Care Excellence

Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years

Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years Technology appraisal guidance TA554 Published: 21 December 2018 ...
National Institute for Health and Care Excellence

Alpelisib with fulvestrant for treating hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer (terminated appraisal)

Guidance Standards and indicators Clinical Knowledge Summaries (CKS) British National Formulary (BNF) BNF for Children (BNFC) Life sciences Library and knowledge services What NICE does Implementing ...
National Institute for Health and Care Excellence

COVID-19 rapid guideline: critical care in adults

This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.
National Institute for Health and Care Excellence

Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer

Evidence-based recommendations on dabrafenib (Tafinlar) plus trametinib (Mekinist) for BRAF V600 mutation-positive advanced non-small-cell lung cancer in adults. There is a commercial access agreement ...
National Institute for Health and Care Excellence

Intrapartum care

This guideline covers the care of pregnant women and pregnant trans and non-binary people and their babies during labour and immediately after birth. It focuses on women and pregnant people who give ...